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1. INTRODUCTION {#mgg3778-sec-0005}
===============

Colorectal cancer (CRC) is one of the most common gastrointestinal cancers worldwide with higher morbidity and mortality caused by biological interactions of various signaling pathways (Li & Gu, [2005](#mgg3778-bib-0012){ref-type="ref"}). During the past few decades, with the change in modern lifestyle and dietary habit, the incidence and mortality of CRC have been increasing rapidly in China. Currently, CRC is the fifth commonest malignancy in China (Chen, Zheng, Zeng, & Zhang, [2015](#mgg3778-bib-0003){ref-type="ref"}). The exact mechanisms underlying the development and progression of CRC remain generally unknown. According to a genetic model for colorectal tumorigenesis, genetic mutation is a critical accelerant contributing to malignant progression of CRC (Fearon & Vogelstein, [1990](#mgg3778-bib-0006){ref-type="ref"}). Cancer‐analyses of cohorts of twins have shown that inherited genetic factors accounts for about 35% of the variance in CRC susceptibility (Lichtenstein et al., [2000](#mgg3778-bib-0013){ref-type="ref"}). These findings suggest that genetic factors significantly influence CRC susceptibility.

Long noncoding RNA (lncRNAs) refers to noncoding RNAs consisting of more than 200 nucleotides in length with important biological functions. The abnormal expression of lncRNAs plays an important role in different physiological and pathological processes, especially to the occurrence and development of tumors (Beckedorff, Amaral, Deocesano‐Pereira, & Verjovski‐Almeida, [2013](#mgg3778-bib-0001){ref-type="ref"}; Prensner & Chinnaiyan, [2011](#mgg3778-bib-0017){ref-type="ref"}; Rossi & Antonangeli, [2014](#mgg3778-bib-0018){ref-type="ref"}). The MIR155 host gene (*MIR155HG*) is an lncRNA that has identified to be an important regulator of many physiological and pathological processes involved in hematopoiesis, inflammation, immunity, and tumorigenesis (Chang et al., [2011](#mgg3778-bib-0002){ref-type="ref"}; Hu, Fong, Largman, & Shen, [2010](#mgg3778-bib-0009){ref-type="ref"}; Kohlhaas et al., [2009](#mgg3778-bib-0011){ref-type="ref"}; Van den Berg et al., [2003](#mgg3778-bib-0023){ref-type="ref"}; Vargova et al., [2011](#mgg3778-bib-0024){ref-type="ref"}). Studies have confirmed that *MIR155HG* overexpressed in acute myeloid leukemia, Hodgkin\'s lymphoma and chronic lymphoblastic leukemia (Elton, Selemon, Elton, & Parinandi, [2013](#mgg3778-bib-0005){ref-type="ref"}). In addition, experimental results demonstrated that downregulation of *MIR155HG* inhibited the growth of gliomas in vitro and in vivo (Wu et al., [2017](#mgg3778-bib-0026){ref-type="ref"}). Previous studies have shown lncRNA *MIR155HG* hold potential to be used as prognostic biomarkers in CRC patients (Thiele et al., [2018](#mgg3778-bib-0021){ref-type="ref"}).

Single‐nucleotide polymorphisms (SNPs) are the most common types of genetic variations that affect disease risk by altering the expression of related genes. As far as we know, there were three studies have reported the association of *MIR155HG*/miR‐155 SNPs with multiple sclerosis (Paraboschi et al., [2011](#mgg3778-bib-0016){ref-type="ref"}), atopic eczema (Sääf et al., [2013](#mgg3778-bib-0019){ref-type="ref"}), and epilepsy (Tao et al., [2015](#mgg3778-bib-0020){ref-type="ref"}). Only three SNPs (rs2829803, rs2282471, and rs2829806) in multiple sclerosis and two SNPs (rs969885 and rs987195) in epilepsy were identified as the genetic susceptibility factors. However, the exact relation between *MIR155HG* SNPs and CRC risk is still undetermined.

In the current study, we performed a case--control study among the Chinese Han population aimed to explore the association between *MIR155HG* SNPs and CRC risk from the perspective of molecular genetics. Our results will help to understand the pathological factors affecting the development of CRC, and thus provide a theoretical basis for the prevention and early detection of CRC.

2. MATERIALS AND METHODS {#mgg3778-sec-0006}
========================

2.1. Subjects {#mgg3778-sec-0007}
-------------

In the present ongoing case--control study, a total of 514 CRC patients and 510 age‐ and sex‐matched healthy controls were consecutively recruited at the Shaanxi Provincial Cancer Hospital. All the individuals were genetically unrelated ethnic northwest Han Chinese and all patients were diagnosed with colorectal cancer by pathological analysis. We excluded the patients who had undergone chemotherapy or irradiation from the current study. Subjects had no history of hereditary or malignant diseases. The clinical features of patients were collected from the patients' medical records provided, including age, gender, clinical stage, and lymph node metastasis (LNM). A standardized epidemiological questionnaire was used to collect subject\'s demographic and personal information and all individuals were informed of the purpose and experimental procedures of the study.

2.2. DNA extraction and genotyping {#mgg3778-sec-0008}
----------------------------------

Genomic DNA was extracted from blood samples using the commercially available GoldMag‐Mini Purification Kit (GoldMag Co. Ltd, Xi\'an, China) according to the manufacturer\'s instructions and the concentration and quality of the DNA were measured on a Nanodrop 2000 spectrophotometer (Thermo Scientific, USA). Eight SNPs with minor allele frequencies (MAFs) \>5%, referenced from the 1,000 Genomes database (<http://www.internationalgenome.org/>), were selected for further analysis. Agena MassARRAY Assay Design Software (version 3.0, Agena Bioscience, San Diego, CA) was used to design multiplexed SNP MassEXTEND assay (Gabriel, Ziaugra, & Tabbaa, [2009](#mgg3778-bib-0007){ref-type="ref"}). And Agena MassARRAY RS1000 was used to detect SNP genotyping. Data management and analysis were conducted using Agena Software (version 4.0, Agena, San Diego, CA) (Duan et al., [2014](#mgg3778-bib-0004){ref-type="ref"}; Geng et al., [2015](#mgg3778-bib-0008){ref-type="ref"}).

2.3. Bioinformatics analysis {#mgg3778-sec-0009}
----------------------------

HaploReg v4.1 (<https://pubs.broadinstitute.org/mammals/haploreg/haploreg.php>) database can be used to study the annotation of noncoding genomes on haplotype blocks, including candidate regulatory SNPS of disease‐related sites. We used HaploReg v4.1 to predict the potential functions of candidate SNPs.

2.4. Statistical analyses {#mgg3778-sec-0010}
-------------------------

The Hardy--Weinberg Equilibrium (HWE) was tested by using chi‐square test in the healthy control group (Table [S1](#mgg3778-sup-0001){ref-type="supplementary-material"}). The odds ratios (ORs), 95% confidence intervals (CIs) and *p* values were calculated by the conditional logistic regression model with the PLINK software version 1.07 (<http://www.cog-genomics.org/plink2/>) to assess the risk for CRC altered by a certain allele and genotype. Four models (genotype, dominant, recessive, and additive) were used to assess the association between each genotype and the risk of CRC (Zhang et al., [2014](#mgg3778-bib-0028){ref-type="ref"}). Moreover, the Haploview software package (version 4.2) and SHEsis software platform were used to analyze the pairwise linkage disequilibrium (LD), haplotype construction, and genetic association of polymorphism loci. In the case--control study, the SPSS 20.0 software was used to calculate the difference in basic information between patients and healthy control group, including age, gender, etc. The adjusted *p*value of less than 0.05 was deemed as statistically significant.

3. RESULTS {#mgg3778-sec-0011}
==========

3.1. Characteristic of the study participates {#mgg3778-sec-0012}
---------------------------------------------

We recruited 514 cases (285 males and 229 females; mean age, 60.27 ± 11.81) and 510 controls (286 males and 224 females; mean age, 60.13 ± 10.61) for this study. The characteristics of cases and controls were showed in Table [1](#mgg3778-tbl-0001){ref-type="table"}. Statistical analysis results showed that there was no significant difference in age and gender distribution between cases and controls (*p* \> 0.05).

###### 

Characteristics of the study population

                Cases           Controls        *p*
  ------------- --------------- --------------- ---------------------------------------------
  Total         514             510              
  Age                                           0.092[a](#mgg3778-note-0005){ref-type="fn"}
  Mean ± *SD*   60.27 ± 11.81   60.13 ± 10.61    
  Sex                                           0.850^b^
  Male          285 (55.4%)     286 (56.1%)      
  Female        229 (44.6%)     224 (43.9%)      
  Absence       38 (7.4%)                        
  Stage                                          
  I‐II          146 (28.4%)                      
  III‐IV        212 (41.2%)                      
  Absence       156 (30.4%)                      
  LNM                                            
  Negative      170 (33.1%)                      
  Positive      188 (36.6%)                      
  Absence       156 (30.3%)                      

Abbreviations: *SD*: standard deviation; BMI: body mass index; LNM: lymph node metastasis.

*p* values were calculated from independent sample *t* test.

*p* values were calculated from two‐sided χ^2^ test.
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3.2. Basic information and potential functions of the selected SNPs {#mgg3778-sec-0013}
-------------------------------------------------------------------

Table [2](#mgg3778-tbl-0002){ref-type="table"} displays the basic information of eight SNPs in *MIR155HG,* including gene, chromosome, position, role, alleles, minor allele frequency (MAF), and functional effects. All SNPs were consistent with Hardy--Weinberg equilibrium (HWE) in the controls (*p* \> 0.05). Additionally, we used HaploRegv4.1 to annotate the functional elements containing these selected SNPs. The results showed that these SNPs were involved in the regulation related to DNAase, marked promoter histone, changed motifs, GRASP QTL hits, selected eQTL hits enhancer histones, bound proteins, suggesting they might influence the related genes expression in this way.

###### 

Basic information of candidate SNPs in the study

  SNP ID       Genes      Chr.    Position     Alleles A/B   MAF     *p*‐HWE[a](#mgg3778-note-0009){ref-type="fn"}   *p* [b](#mgg3778-note-0010){ref-type="fn"}   OR (95% CI)   HaploReg            
  ------------ ---------- ------- ------------ ------------- ------- ----------------------------------------------- -------------------------------------------- ------------- ------------------- ---------------------------------------------------------------------------------------------------------------------------
  rs4143370    MIR155HG   chr21   25,564,661   C/G           0.175   0.165                                           0.053                                        0.518         1.08 (0.86--1.36)   Promoter histone marks, Enhancer histone marks, DNAse, Proteins bound, Motifs changed, Selected eQTL hits
  rs77218221   MIR155HG   chr21   25,565,063   C/T           0.051   0.050                                           1.000                                        0.952         1.01 (0.68--1.51)   Promoter histone marks, Enhancer histone marks, Motifs changed
  rs12482371   MIR155HG   chr21   25,566,041   C/T           0.318   0.278                                           0.151                                        **0.047**     1.21 (1.00--1.47)   Promoter histone marks, Enhancer histone marks, DNAse, Proteins bound, Motifs changed, Selected eQTL hits
  rs77699734   MIR155HG   chr21   25,566,995   C/G           0.083   0.091                                           1.000                                        0.823         0.97 (0.71--1.31)   Promoter histone marks, Enhancer histone marks, DNAse, Proteins bound
  rs11911469   MIR155HG   chr21   25,567,971   A/C           0.122   0.116                                           0.522                                        0.691         1.06 (0.81--1.38)   Promoter histone marks, Enhancer histone marks, DNAse, Proteins bound, Motifs changed
  rs1893650    MIR155HG   chr21   25,568,503   C/T           0.205   0.167                                           0.751                                        **0.025**     1.29 (1.03--1.62)   Promoter histone marks, Enhancer histone marks, DNAse, Proteins bound, Motifs changed, GRASP QTL hits, Selected eQTL hits
  rs34904192   MIR155HG   chr21   25,569,623   A/G           0.265   0.255                                           0.817                                        0.636         1.05 (0.86--1.28)   Promoter histone marks, Enhancer histone marks, DNAse, Proteins bound, Motifs changed, Selected eQTL hits
  rs928883     MIR155HG   chr21   25,571,713   A/G           0.414   0.460                                           1.000                                        **0.037**     0.83 (0.70--0.99)   Enhancer histone marks, DNAse, Proteins bound, Motifs changed, Selected eQTL hits

Bold values indicate statistical significance (*p* \< 0.05).

Abbreviations: SNP: single‐nucleotide polymorphism; MAF: minor allele frequency; HWE: Hardy--Weinberg equilibrium; OR: odds ratio; 95% CI: 95% confidence interval.

HWE *p* values were calculated from Fisher\'s exact test.

*p* values were calculated from two‐sided χ^2^ test.
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3.3. SNPs and the risk of CRC {#mgg3778-sec-0014}
-----------------------------

In Table [2](#mgg3778-tbl-0002){ref-type="table"}, we identified three significant SNPs variants associated with the CRC risk by the χ^2^test. They were the allele "C" of rs12482371 (OR = 1.21, 95% CI = 1.00--1.47, *p* = 0.047), the allele "C" of rs1893650 (OR = 1.29, 95% CI = 1.03--1.62, *p* = 0.025), and the allele "A" of rs928883 (OR = 0.83, 95% CI = 0.70--0.99, *p* = 0.037). Results of the genetic model analysis are showed in Table [3](#mgg3778-tbl-0003){ref-type="table"}. The result indicated that rs12482371 moderately increased the risk of CRC in genotype model (OR = 1.35, 95% CI = 1.04--1.75, *p* = 0.024) and dominant model (OR = 1.33, 95% CI = 1.04--1.70, *p* = 0.022), respectively. We also determined that rs1893650 increased risk of CRC (TC‐CC vs. TT, OR = 1.32, 95% CI: 1.02--1.71, *p* = 0.036), conversely, that rs928883 was associated with reduced susceptibility of CRC (AA vs. GG, OR = 0.70, 95% CI: 0.49--0.99, *p* = 0.046). In additive model, the rs1893650 and rs928883 also related with CRC risk (*p* \< 0.05).

###### 

Analysis of association between rs12482371, rs1893650, and rs928883 polymorphism and risk of CRC

  SNP ID       Model      Genotype   Case (*N*)          Control (*N*)       Crude               Adjusted[a](#mgg3778-note-0012){ref-type="fn"}               
  ------------ ---------- ---------- ------------------- ------------------- ------------------- ------------------------------------------------ ----------- ---
  rs12482371   Genotype   CC         238                 272                 1                                                                                 
  CT           225        191        1.34 (1.04--1.75)   **0.025**           1.35 (1.04--1.75)   **0.024**                                                    
  TT           51         46         1.27 (0.82--1.96)   0.286               1.27 (0.82--1.96)   0.288                                                        
  Dominant     CC         238        272                 1                                       1                                                            
  CT‐TT        276        237        1.33 (1.04--1.70)   **0.023**           1.33 (1.04--1.70)   **0.022**                                                    
  Recessive    CC‐CT      463        463                 1                                       1                                                            
  TT           51         46         1.11 (0.73--0.69)   0.629               1.11 (0.73--0.68)   0.633                                                        
  Additive     ---        ---        ---                 1.21 (0.99--1.45)   0.051               1.21 (0.99--1.46)                                0.051       
  rs1893650    Genotype   TT         326                 355                 1                                                                                 
               TC         165        140                 1.28 (0.98--1.68)   0.071               1.28 (0.98--1.68)                                0.071       
               CC         23         15                  1.67 (0.86--3.26)   0.132               1.67 (0.86--3.25)                                0.134       
  Dominant     TT         326        355                 1                                       1                                                            
               TC‐CC      188        155                 1.32 (1.02--1.71)   **0.036**           1.32 (1.02--1.71)                                **0.036**   
  Recessive    TT‐TC      491        495                 1                                       1                                                            
               CC         23         15                  1.55 (0.80--3.00)   0.197               1.54 (0.80--2.99)                                0.199       
  Additive     ---        ---        ---                 1.29 (1.03--1.61)   **0.026**           1.29 (1.03--1.61)                                **0.027**   
  rs928883     Genotype   GG         175                 148                 1                                                                                 
               GA         242        254                 0.81 (0.61--1.07)   0.132               0.81 (0.61--1.07)                                0.132       
               AA         88         107                 0.70 (0.49--0.99)   **0.046**           0.70 (0.49--0.99)                                **0.046**   
  Dominant     GG         175        148                 1                                       1                                                            
               GA‐AA      330        361                 0.77 (0.59--1.01)   0.057               0.77 (0.59--1.01)                                0.057       
  Recessive    GG‐GA      417        402                 1                                       1                                                            
               AA         88         107                 0.79 (0.58--1.09)   0.147               0.79 (0.58--1.09)                                0.147       
  Additive     ---        ---        ---                 0.83 (0.70--0.99)   **0.038**           0.83 (0.70--0.99)                                **0.038**   

Bold values indicate statistical significance (*p* \< 0.05).

Adjusted for age and sex in a conditional logistic regression model.

*p* values were calculated from wald test.
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Stratified analysis revealed the relationships of *MIR155HG* SNPs with CRC risk and the results were exhibited in Table [4](#mgg3778-tbl-0004){ref-type="table"}. The results showed that the allele "A" of rs9383938 was associated with a reduced risk of CRC in individuals under 60 years old (OR = 0.77, 95% CI = 0.59--0.99, *p* = 0.047), but the rs12482371 increased CRC risk in dominant model only among individuals over 60 years old (OR = 0.77, 95% CI = 0.59--0.99, *p* = 0.047). Rs12482371 and rs1893650 were associated with CRC risk in female under allele model, dominant model and additive model (*p* \< 0.05). In addition, the rs1893650 played a risk role only in colon cancer under allele model, dominant model and additive model (*p* \< 0.05). The genotypes distribution of rs11911469 and rs34904192 were significantly different between grades I‐II and III‐IV patients, as well as between lymph node metastasis and without metastasis patients (*p* \< 0.05).

###### 

Stratification analysis of the association of *MIR155HG* polymorphisms with CRC under genetic models

                       SNP ID                         *P* [a](#mgg3778-note-0016){ref-type="fn"}, OR (95% CI)                                                                                                                               
  -------------------- ------------------------------ --------------------------------------------------------- ------------------------------ ------------------------------ ------------------------------ ------------------------------ ------------------------------
  Age                                                                                                                                                                                                                                        
  ≤60                  rs12482371                     0.344, 1.14 (0.87--1.51)                                  0.606, 1.23 (0.63--2.40)       0.320, 1.21 (0.83--1.77)       0.292, 1.21 (0.85--1.74)       0.724, 1.12 (0.59--2.14)       0.329, 1.15 (0.87--1.53)
  rs928883             **0.047**, 0.77 (0.59--0.99)   **0.037**, 0.55 (0.31-- 0.96)                             0.242, 0.78 (0.51--1.18)       0.102, 0.72 (0.49--1.07)       0.080, 0.64 (0.39--1.05)       **0.037**, 0.75 (0.57--0.98)   
  \>60                 rs12482371                     0.068, 1.27 (0.98--1.65)                                  0.346, 1.32 (0.74--2.35)       **0.033**,1.48 (1.03--2.12)    **0.033**,1.45 (1.03--2.03)    0.702, 1.11 (0.64--1.94)       0.077, 1.26 (0.98--1.62)
  rs928883             0.327, 0.89 (0.70--1.13)       0.391, 0.81 (0.51--1.30)                                  0.272, 0.80 (0.54--1.19)       0.247, 0.81 (0.56--1.16)       0.709, 0.92 (0.61--1.39)       0.340, 0.89 (0.71--1.13)       
  Sex                                                                                                                                                                                                                                        
  Male                 rs12482371                     0.463, 1.10 (0.85--1.42)                                  0.977, 0.99 (0.56--1.77)       0.154, 1.29 (0.91--1.82)       0.226, 1.23 (0.88--1.70)       0.663, 0.88 (0.51--1.54)       0.467, 1.10 (0.85--1.41)
  rs1893650            0.447, 1.12 (0.83--1.51)       0.472, 1.39 (0.57--3.36)                                  0.651, 1.09 (0.76--1.56)       0.536, 1.12 (0.79--1.58)       0.505, 1.35 (0.56--3.26)       0.451, 1.12 (0.83--1.51)       
  rs928883             0.214, 0.86 (0.68--1.09)       0.208, 0.74 (0.47--1.18)                                  0.687, 0.93 (0.63--1.35)       0.416, 0.86 (0.61--1.23)       0.225, 0.78 (0.52--1.17)       0.226, 0.87 (0.69--1.09)       
  Female               rs12482371                     **0.030**, 1.38 (1.03--1.84)                              0.103, 1.74 (0.89--3.40)       0.075, 1.43 (0.96--2.11)       **0.038**, 1.48 (1.02--2.15)   0.224, 1.49 (0.78--2.85)       **0.034**, 1.36 (1.02--1.81)
  rs1893650            **0.012**, 1.54 (1.10--2.17)   0.152, 2.11 (0.76--5.85)                                  **0.028**, 1.58 (1.05--2.39)   **0.015**, 1.63 (1.10--2.42)   0.243, 1.83 (0.66--5.03)       **0.014**, 1.53 (1.09--2.15)   
  rs928883             0.083, 0.79 (0.61--1.03)       0.112, 0.64 (0.36--1.11)                                  0.069, 0.67 (0.44--1.03)       **0.047**, 0.67 (0.44--0.99)   0.413, 0.81 (0.50--1.33)       0.072, 0.78 (0.59--1.02)       
  Tumor types                                                                                                                                                                                                                                
  Colon cancer         rs1893650                      **0.031**, 1.36 (1.03--1.81)                              0.189, 1.74 (0.76--3.97)       0.067, 1.38 (0.97--1.95)       **0.041**,1.42 (1.02--1.98)    0.280, 1.57 (0.69--3.55)       **0.035**, 1.36 (1.02--1.80)
  Rectal cancer        rs1893650                      0.393, 1.13 (0.85--1.50)                                  0.949, 1.03 (0.41--2.58)       0.295, 1.20 (0.86--1.67)       0.317, 1.18 (0.85--1.63)       0.960, 0.98 (0.39--2.43)       0.392, 1.13 (0.85--1.50)
  Stage                                                                                                                                                                                                                                      
  III‐IV versus I‐II   rs11911469                     **0.001**, 0.47 (0.30--0.75)                              0.329, 0.47 (0.10--2.15)       **0.002**, 0.43 (0.25--0.72)   **0.001**, 0.43 (0.26--0.72)   0.455, 0.56 (0.12--2.56)       **0.002**, 0.49 (0.31--0.77)
  rs34904192           0.225, 1.24 (0.88--1.75)       0.731, 0.88 (0.41--1.87)                                  **0.011**, 1.85 (1.15--2.97)   **0.043**, 1.57 (1.01--2.42)   0.357, 0.71 (0.34--1.48)       0.253, 1.21 (0.87--1.69)       
  LNM                                                                                                                                                                                                                                        
  (+) versus (‐)       rs11911469                     0.064, 0.66 (0.43--1.03)                                  0.842, 0.87 (0.21--3.57)       **0.039**, 0.58 (0.35--0.97)   **0.046**, 0.61 (0.37--0.99)   0.973, 0.98 (0.24--4.01)       0.079, 0.68 (0.44--1.05)
  rs34904192           0.184, 1.26 (0.90--1.76)       0.594, 0.82 (0.39--1.72)                                  **0.002**, 2.07 (1.30--3.30)   **0.017**, 1.68 (1.10--2.57)   0.216, 0.63 (0.31--1.31)       0.212, 1.23 (0.89--1.68)       

Bold values indicate statistical significance (*p* \< 0.05).

Abbreviations: BMI: body mass index; LNM: lymph node metastasis.

*p* values were calculated from wald test.
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3.4. Haplotype analysis {#mgg3778-sec-0015}
-----------------------

Two blocks were detected in *MIR155HG* SNPs by haplotype analyses (Figure [1](#mgg3778-fig-0001){ref-type="fig"}). Block 1 contained three SNPs (rs4143370\|rs77218221\|rs12482371). Block 2 contained five SNPs (rs77699734\|rs11911469\|rs1893650\|rs34904192\|rs928883). The results of the relationships between the haplotypes and the CRC risk were listed in Table [5](#mgg3778-tbl-0005){ref-type="table"}. In block 1, haplotype "CTT" and haplotype "GTC" were more prevalent in case group than control group and were significantly associated with a reduced the risk of CRC ("CTT": OR = 0.83, 95% CI = 0.69--0.99, *p* = 0.047; "GTC": OR = 0.82, 95% CI = 0.69--0.97, *p* = 0.021). In block 2, haplotype "CATGA" and haplotype "CACGG" were also associated with a reduced the risk of CRC. ("CATGA": OR = 0.81, 95% CI = 0.68--0.97, *p* = 0.021; "CACGG": OR = 0.78, 95% CI = 0.62--0.97, *p* = 0.028).

![Haplotype block map for the SNPs in *MIR155HG* gene. The numbers inside the diamonds indicate the D′ for pairwise analyses. Block 1 indicates that there is a strong linkage disequilibrium between rs4143370, rs77218221, and rs12482371. Block 2 indicates that there is a strong linkage disequilibrium between rs77699734, rs11911469, rs1893650, rs34904192, and rs928883](MGG3-7-e778-g001){#mgg3778-fig-0001}

###### 

Haplotype frequencies of *MIR155HG* SNPs and the association with CRC

  Block     Haplotype                                                 Haplotype Frequency   OR(95% CI)          *P* [a](#mgg3778-note-0019){ref-type="fn"}   
  --------- --------------------------------------------------------- --------------------- ------------------- -------------------------------------------- -----------
  Block 1   rs4143370\|rs77218221\|rs12482371                                                                                                                 
  CTT       0.681                                                     0.722                 0.83 (0.69--0.99)   **0.047**                                    
  CCC       0.950                                                     0.950                 1.01 (0.68--1.49)   0.972                                        
  CTC       0.126                                                     0.115                 1.10 (0.85--1.41)   0.471                                        
  GTC       0.505                                                     0.557                 0.82 (0.69--0.97)   **0.021**                                    
  Block 2   rs77699734\|rs11911469\|rs1893650\|rs34904192\|rs928883                                                                                           
            CATGA                                                     0.409                 0.459               0.81 (0.68--0.97)                            **0.021**
            GATAG                                                     0.912                 0.909               1.04 (0.76--1.40)                            0.826
            CATAG                                                     0.176                 0.164               1.08 (0.87--1.35)                            0.483
            CACGG                                                     0.795                 0.833               0.78 (0.62--0.97)                            **0.028**
            CCTGG                                                     0.878                 0.882               0.97 (0.74--1.26)                            0.806

Bold values indicate statistical significance (*p* \< 0.05).

OR: odds ratio; 95% CIs: 95% confidence intervals.

*p* values were calculated by conditional logistic regression with adjustment for age and gender.
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4. DISCUSSION {#mgg3778-sec-0016}
=============

To date, several studies have investigated the association between genetic polymorphisms and risk of CRC, and identified a variety of susceptibility genes and SNPs for CRC in different populations. However, studies based on variants in the *MIR155HG* gene are infrequent in the occurrence and development of colorectal cancer. In this case--control study, we first time evaluated the relationships between eight SNPs in lncRNA *MIR155HG* and the CRC risk in the Chinese population. Five novel SNPs (rs12482371, rs1893650, rs92888, rs11911469, and rs34904192) in *MIR155HG* were found significantly influence the CRC susceptibility.

The lncRNA *MIR155HG* was found to be a marker of early stage cancer development (Thiele et al., [2018](#mgg3778-bib-0021){ref-type="ref"}). *MIR155HG* gene is activated by MYB transcription factor and thus upregulated, which in turn leaded to downregulation of many tumor suppressor genes (Nielsen et al., [2007](#mgg3778-bib-0015){ref-type="ref"}). Moreover, the *MIR155HG* transcript is processed into microRNA‐155 (miR‐155). MiR‐155 is a multifunctional miRNA that plays varied roles in immune, inflammatory, and cardiovascular diseases (Elton et al., [2013](#mgg3778-bib-0005){ref-type="ref"}). MiR‐155 has been identified as a negative regulator of tumor protein 53 and DNA mismatch repair genes (Valeri et al., [2010](#mgg3778-bib-0022){ref-type="ref"}). Especially, miR‐155‐5p was found to be overexpressed in solid tumors of diverse origin, including colon cancer (Zhang et al., [2013](#mgg3778-bib-0027){ref-type="ref"}). Recent studies have shown that miR‐155 may work as a tumor suppressor (Kim et al., [2016](#mgg3778-bib-0010){ref-type="ref"}), and Liu et al. found that overexpressed miR‐155 lead to apoptosis and suppresses cell proliferation in CRC (Liu, Chen, Xiang, & Gu, [2018](#mgg3778-bib-0014){ref-type="ref"}). Therefore, we hypothesized that the *MIR155HG* may play a critical role in promoting CRC progression, and its mechanism may be achieved by producing miR‐155. Further functional researches are still required to explore the underlying mechanisms of *MIR155HG*.

For many years, intron sequences have been considered essentially nonfunctional. However, subsequent study showed that intron‐containing genes presented higher levels of transcription when compared to intron‐less genes in mammalian cells, suggesting that introns may be enhancers of transcription (Vaz‐Drago, Custódio, & Carmo‐Fonseca, [2017](#mgg3778-bib-0025){ref-type="ref"}). Rs12482371, rs1893650, rs92888, rs11911469, and rs34904192 were all located in the intron region of *MIR155HG*, therefore combining the predicted functions of the database, we hypothesized that these SNPs may enhance the translation of *MIR155HG* gene thereby affect the risk of CRC. The results also provide new evidence for the early detection of CRC.

Some limitations need to be considered in our study. First, this study was only performed in Chinese Han populations. Due to differences in genetic background, the role of these SNPs in other ethnic groups remains to be revealed. Second, CRC is a complex disease affected by a variety of genetic and environmental factors. The limitations of the data make it difficult to explore the interaction between genetic polymorphism and environmental factors.

In conclusion, our study of SNPs in *MIR155HG* confirmed the relationships between genetic polymorphisms and CRC in the Chinese Han population. We hope this research provides a new direction for the detection and diagnosis of CRC and permits early prevention of this disease. To better understand the relationship, further analyses should increase sample size and clinical data, as well as functional experiments, and require repeated studies in different ethnic populations.
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